GlassScriptPhysician profile
Madhavi Bhoomagoud
NPI 1265669089
$12,545.16
in general payments reported to CMS, 2019-2025
38 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,492 · 2020: $1,407 · 2021: $1,892 · 2022: $2,241 · 2023: $2,176 · 2024: $1,813 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,343 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,342.56 |
| Education | $170.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,988.27 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Gilead Sciences, INC. | $1,722.91 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,369.87 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $905.75 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $883.57 | 2019-2024 | Linzess |
| Pfizer INC. | $522.34 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $516.27 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $405.77 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $398.21 | 2021-2023 | Sucraid |
| Celgene Corporation | $396.42 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $319.40 | 2023-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $257.36 | 2019-2023 | Rebyota, Cimzia |
| Redhill Biopharma INC. | $176.43 | 2020-2022 | |
| Alfasigma USA, INC. | $161.43 | 2020-2021 | |
| Ardelyx, INC. | $147.58 | 2022-2024 | Ibsrela |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhavi Bhoomagoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.